Lite Strategy LITS
Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies. 10-K, Item 1
- Headquarters
- San Diego, CA
- CEO
- Justin J. File
- Next results
- around Feb 16, 2027
What changed
4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Sep 28, 2026 against Sep 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
7 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 6 checks found nothing to note
-
Auditor change8-K item 4.01 (change in certifying accountant) filed Dec 5, 2025
-
No statement of substantial doubt about going concern
5 more checks with nothing to note
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
4 paragraphs in Risk Factors that were not in the 10-K filed Sep 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Sep 26, 2025 10-K, ITEM 1A
We intend to monitor our assets and income in order to conduct our business activities in a manner such that we do not fall within the definition of “investment company” under the 1940 Act or would qualify under one of the exemptions or exclusions
-
Item 1A · new paragraph · not in the 10-K filed Sep 26, 2025 10-K, ITEM 1A
We expect to continue to incur operating and net losses, as we develop and seek development and/or commercial relationships with other partners for our drug candidates. In addition, because we hold LTC as a primary reserve asset, fluctuations in the market price of LTC, including declines below our acquisition costs, may materially…
-
Item 1A · new paragraph · not in the 10-K filed Sep 26, 2025 10-K, ITEM 1A
We may incorporate the use of AI into our business, operations and offerings in ways which present opportunities as well as challenges and risks, particularly as AI can produce hallucinations and AI agents may take undesired actions, if used.AI systems or input data issues could present inaccurate information, privacy, reputational and…
New risk paragraphs, against peers
Latest 10-K of each, Crypto companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | $48.8M | $65.3M | $0 | $0 |
| Net income | −$32.0M | $18.0M | −$15.9M | −$71.2M |
| Operating cash flow | −$52.5M | −$50.5M | −$20.8M | −$9.1M |
| Free cash flow | −$52.5M | −$50.5M | −$20.8M |
Revenue, FY2017 to FY2026
Ten fiscal years, each from its own 10-K · XBRL · USD
$0 in FY2026−$71.2M in FY2026
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 3, 2026Unregistered share sale 8-K item 3.02
-
BuyOct 26, 2026Glover Nicholas (Director) bought $13K open-market purchase on Jul 22, 2025, reported 1 year late
About the company
Lite Strategy, San Diego, CA · from the 10-K filed Sep 28, 2026
Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies. During fiscal year 2026, we commenced pre-clinical development programs in nononcologic disease indications. We also hold Litecoin (LTC) tokens as a primary reserve asset as part of our broader institutional treasury initiative. We initially built our pipeline by acquiring promising cancer agents and creating value in programs through clinical development, strategic partnerships, and out-licensing or commercialization, as appropriate.
- Headquarters
- San Diego, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- June 30
- Last results
- Jul 30, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Sep 28, 2026 (open at SEC), compared with the 10-K filed Sep 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LITS/export.csv") into a cell.